Company Overview of Octapharma AG
Octapharma AG, a plasma fractionation company, develops, produces, and sells human proteins that are derived from human plasma and human cell-lines in Europe and internationally. It offers haematology products, including Nuwiq, a human coagulation factor VIII used for the treatment and prophylaxis of bleeding in all age groups with haemophilia A; octanate, a human factor VIII/von Willebrand factor (VWF) concentrate, which is used for the treatment and prophylaxis of bleeding in patients with haemophilia A; wilate, a human VWF concentrate that is used for the treatment of patients with von Willebrand disease and haemophilia A; and octanine F, a human factor IX concentrate that is used for the...
Founded in 1983
Key Executives for Octapharma AG
Chairman of Management Board and Chief Executive Officer
Chief Financial Officer and Member of Management Board
Member of Management Board and President of Octapharma Plasma Inc Usa
Member of Management Board and President for Octapharma Usa Inc
Senior Vice President of R&D Plasma - Vienna
Compensation as of Fiscal Year 2016.
Octapharma AG Key Developments
Octapharma Group Reports Earnings Results for the Year 2015
Mar 8 16
Octapharma Group reported earnings results for the year 2015. For the year, the company reported revenue of EUR 1.513 billion, representing an increase of EUR 233 million or 18.2% compared with the 2014. Operating income is reported at EUR 351 million. Net cash from operating activities is reported at EUR 382 million or 25% of revenue and provides the platform for future investments. Pre-tax profit was EUR 363 million. The investment in fixed assets was EUR 115 million in 2015. Adding the investments into research and development, in 2015 the Octapharma Group invested more than EUR 240 million into the future of the company.
FDA Approves Octapharma’S Nuwiq® for the Treatment of Adults and Children with Hemophilia A
Sep 15 15
Octapharma USA announced the U.S. Food and Drug Administration (FDA) has approved NUWIQ®, Antihemophilic Factor (Recombinant), an intravenous therapy for adults and children living with Hemophilia A. The NUWIQ® approval includes on-demand treatment and control of bleeding episodes; routine prophylaxis to reduce the frequency of bleeding episodes; and perioperative management of bleeding. NUWIQ® is the first B-domain deleted recombinant Factor VIII (FVIII) derived from a human cell-line, not chemically modified or fused with another protein, designed for the treatment of patients with Hemophilia A, congenital FVIII deficiency. Hemophilia A impacts the lives of up to 16,000 individuals in the U.S. and their caregivers. Although present therapies for Hemophilia A treatment exist in the U.S., significant challenges still remain, including development of inhibitors and the need for multiple infusions on a prophylactic basis. Octapharma USA is a subsidiary of global human protein products manufacturer Octapharma AG, which develops and manufactures high-purity recombinant and plasma-derived coagulation factor concentrates for patients with bleeding disorders.
The European Commission first approved the therapy in August 2014. NUWIQ®is currently approved in many countries, including the United Kingdom, Australia, Canada, Germany, Italy, Sweden and Argentina.
Octapharma AG Reports Earnings Results for the Year Ended December 31, 2014
Mar 12 15
Octapharma AG reported that net profit for the year ended December 31, 2014 was EUR 236.14 million, compared to EUR 124.40 million for the year ended December 31, 2013. Revenue for the year ended December 31, 2014 was EUR 1.28 billion, compared to EUR 1.15 billion for the year ended December 31, 2013. Operating income for the year ended December 31, 2014 was EUR 271.19 million, compared to EUR 149.92 million for the year ended December 31, 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions